The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial

OBJECTIVES: The CAMERA-II trial compared two tight-control, treat-to-target strategies, initiating methotrexate with prednisone (MTX+pred) or MTX with placebo (MTX+plac), in early RA-patients. The multi-biomarker disease activity (MBDA) blood test objectively measures RA disease activity with a scor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurgens, M. S., Safy-Khan, M., de Hair, M. J. H., Bijlsma, J. W. J., Welsing, P. M. J., Tekstra, J., Lafeber, F. P. J. G., Sasso, E. H., Jacobs, J. W. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487793/
https://www.ncbi.nlm.nih.gov/pubmed/32907614
http://dx.doi.org/10.1186/s13075-020-02293-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487793/
https://www.ncbi.nlm.nih.gov/pubmed/32907614
http://dx.doi.org/10.1186/s13075-020-02293-x

Ejemplares similares